2018 American Society of Hematology Annual Meeting*

Hematology 2018 Conference Image
Download All
December 1-4, 2018; San Diego, California
Key myeloma abstracts selected by Shaji Kumar, MD, and Sagar Lonial, MD, presented at the 2018 ASH annual meeting.
Shaji K. Kumar, MD
Sagar Lonial, MD

Multiple Myeloma

Slidesets FORTE: KRd Induction/Consolidation With ASCT vs 12 Cycles of KRd vs KCd Induction/Consolidation With ASCT in ASCT-Eligible Newly Diagnosed MM
Slidesets GRIFFIN: Efficacy and Updated Safety From Phase II Study of Daratumumab + VRd vs VRd Alone for Newly Diagnosed Multiple Myeloma
Slidesets TOURMALINE-MM3: Phase III Trial of Oral Ixazomib as Maintenance Therapy After ASCT in Patients With Newly Diagnosed Multiple Myeloma
Slidesets Phase II Trial of Daratumumab + Ixazomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Slidesets Phase III Trial of Rd Followed by R vs Continuous Rd in Intermediate-Fit Elderly Patients With Newly Diagnosed Multiple Myeloma
Slidesets Planned Interim Analysis of Phase II HOVON 143 Study of Ixazomib, Daratumumab, and Low-Dose Dex in Unfit, Frail Patients With Newly Diagnosed Multiple Myeloma
Slidesets Phase II STORM Trial Part 2: Selinexor + Low-Dose Dexamethasone in Penta-Refractory MM
Slidesets LEGEND-2 Updated Analysis: Phase I Study of LCAR-B38M CAR T-Cell Therapy in Patients With R/R Multiple Myeloma
Slidesets First-in-Human Phase I Trial of AMG 420, a BiTE Construct Binding to BCMA x CD3, in Heavily Pretreated Patients With Multiple Myeloma
Slidesets Phase III MAIA: Daratumumab + Len/Dex vs Len/Dex in Transplantation-Ineligible Newly Diagnosed Multiple Myeloma

Review expert insights on key practice-changing studies in multiple myeloma presented at the Hematology 2018 annual meeting in San Diego.

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: March 6, 2019 Expired: No longer available for credit
Provided by the Annenberg Center for Health Sciences at Eisenhower.
ACHS Logo
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Incyte
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Seagen
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings